Home > Rheumatology > EULAR 2020 > Ankylosing Spondylitis > Worse response axSpA patients to second TNFi versus first TNFi

Worse response axSpA patients to second TNFi versus first TNFi

Presented By
Dr Santiago Rodrigues-Manica, Hospital Egas Moniz, Portugal
Conference
EULAR 2020
It has become common practice to start a second tumour necrosis factor inhibitor (TNFi) in patients with axial spondyloarthritis (axSpA) who discontinue their first TNFi [1]. However, evidence on the effectiveness of this strategy in clinical practice has been limited. Moreover, it remains unclear if the reason for discontinuation of the first TNFi influences the response to the second. Dr Santiago Rodrigues-Manica (Hospital Egas Moniz, Portugal) and colleagues compared the responses to the first and second TNFi and assessed whether the reason for discontinuation of the first TNFi influences the response to the second TNFi. Data was obtained from the Portuguese ReumaPt registry and included  axSpA patients who had discontinued their first TNFi and started a second TNFi and had complete data available on Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at baseline, 3 months, and 6 months f...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on